Research and Development Expenses Breakdown: Amgen Inc. vs Evotec SE

A Decade of Innovation: Amgen Inc. vs. Evotec SE

In the ever-evolving landscape of biotechnology, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Evotec SE have demonstrated contrasting approaches to R&D investment. Amgen, a giant in the biotech industry, has consistently allocated substantial resources, with expenses peaking at nearly 5 billion USD in 2021, reflecting a 35% increase from 2017. In contrast, Evotec SE, a smaller player, has shown a remarkable growth trajectory, with R&D expenses surging by over 500% from 2014 to 2022. This stark difference highlights the diverse strategies employed by these companies in their quest for scientific breakthroughs. As we look to the future, understanding these trends offers valuable insights into the competitive dynamics of the biotech sector.